Kiniksa Pharmaceuticals International (KNSA) to Release Earnings on Tuesday

Key Points

• Kiniksa will report Q1 2026 results before the market opens on April 28, 2026 at 8:30 AM ET, with analysts modeling EPS of $0.21 and revenue of $207.123 million.
• The company missed EPS estimates last quarter (reported $0.17 vs. $0.29 consensus) despite revenue rising 65% year-over-year to $202.13 million, while analysts still forecast ~$1 EPS for the current fiscal year and ~$2 for next year and place a Moderate Buy consensus with a $56 average target.
• Significant insider selling has occurred recently (61,479 shares worth ~$2.83M over 90 days) even as insiders and institutions each own roughly 53% of the stock, a notable shareholder-concentration dynamic.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) is anticipated to post its Q1 2026 results before the market opens on Tuesday, April 28th. Analysts expect Kiniksa Pharmaceuticals International to post earnings of $0.21 per share and revenue of $207.1230 million for the quarter. Individuals may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Tuesday, April 28, 2026 at 8:30 AM ET.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last announced its quarterly earnings results on Tuesday, February 24th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.12). Kiniksa Pharmaceuticals International had a net margin of 8.71% and a return on equity of 11.48%. The business had revenue of $202.13 million during the quarter, compared to the consensus estimate of $200.86 million. During the same period in the previous year, the business posted ($0.12) EPS. Kiniksa Pharmaceuticals International's revenue was up 65.0% compared to the same quarter last year. On average, analysts expect Kiniksa Pharmaceuticals International to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Kiniksa Pharmaceuticals International Stock Performance

Shares of NASDAQ KNSA opened at $42.79 on Friday. Kiniksa Pharmaceuticals International has a fifty-two week low of $20.19 and a fifty-two week high of $50.03. The stock has a market cap of $3.28 billion, a price-to-earnings ratio of 57.82 and a beta of 0.06. The firm's 50-day simple moving average is $45.98 and its 200 day simple moving average is $42.76.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on KNSA. Wall Street Zen raised shares of Kiniksa Pharmaceuticals International from a "hold" rating to a "buy" rating in a research report on Saturday, April 18th. Zacks Research downgraded shares of Kiniksa Pharmaceuticals International from a "hold" rating to a "strong sell" rating in a research report on Friday, April 17th. Canaccord Genuity Group began coverage on shares of Kiniksa Pharmaceuticals International in a research report on Thursday, February 19th. They issued a "buy" rating and a $62.00 price objective for the company. Wells Fargo & Company upped their price objective on shares of Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 25th. Finally, Wedbush upped their price objective on shares of Kiniksa Pharmaceuticals International from $53.00 to $58.00 and gave the stock an "outperform" rating in a research report on Thursday, April 16th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $56.00.

Insider Activity

In other news, CFO Mark Ragosa sold 17,845 shares of the stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $43.28, for a total transaction of $772,331.60. Following the completion of the transaction, the chief financial officer directly owned 12,086 shares of the company's stock, valued at $523,082.08. This represents a 59.62% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Sanj K. Patel sold 7,278 shares of the company's stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $50.01, for a total transaction of $363,972.78. Following the sale, the chief executive officer owned 7,278 shares in the company, valued at $363,972.78. The trade was a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 61,479 shares of company stock worth $2,832,812. 53.48% of the stock is owned by insiders.

Institutional Trading of Kiniksa Pharmaceuticals International

A number of institutional investors have recently modified their holdings of the business. Rubric Capital Management LP lifted its stake in shares of Kiniksa Pharmaceuticals International by 2.3% during the 3rd quarter. Rubric Capital Management LP now owns 4,000,000 shares of the company's stock valued at $155,320,000 after buying an additional 90,194 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its stake in shares of Kiniksa Pharmaceuticals International by 45.3% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,068,263 shares of the company's stock valued at $41,481,000 after buying an additional 332,846 shares in the last quarter. Qube Research & Technologies Ltd lifted its stake in shares of Kiniksa Pharmaceuticals International by 277.8% during the 2nd quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company's stock valued at $24,581,000 after buying an additional 653,236 shares in the last quarter. Millennium Management LLC lifted its stake in shares of Kiniksa Pharmaceuticals International by 8.7% during the 1st quarter. Millennium Management LLC now owns 847,124 shares of the company's stock valued at $18,815,000 after buying an additional 67,452 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its stake in shares of Kiniksa Pharmaceuticals International by 51.8% during the 4th quarter. Goldman Sachs Group Inc. now owns 829,417 shares of the company's stock valued at $34,213,000 after buying an additional 282,907 shares in the last quarter. 53.95% of the stock is currently owned by hedge funds and other institutional investors.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company's core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company's lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still's disease and Schnitzler syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.